Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Vertex Pharmaceuticals

Vertex Pharmaceuticals
1989 FOUNDED
PUBLIC STATUS
1K-5K EMPLOYEES
VRTX STOCK SYMBOL
10 INVESTMENTS
$176.37 SHARE PRICE (As of Monday Closing)
Description

Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, and Symdeko for cystic fibrosis, in addition to several pipeline candidates targeting this market. Vertex's pipeline also includes therapies for cancer, pain, inflammatory diseases, influenza, and other rare diseases.

Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 50 Northern Avenue
  • Boston, MA 02210
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Vertex Pharmaceuticals’s full profile, request a free trial.

Vertex Pharmaceuticals Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$151.80 - $195.81 $45.2B $175.79 $8.46 1.17M 256M

Vertex Pharmaceuticals Financials Summary

In Thousands,
USD
TTM
31-Mar-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 44,451,210 39,909,043 36,687,131 18,151,289
Revenue 3,265,233 3,047,597 2,488,652 1,702,177
EBITDA 811,256 706,780 103,258 75,464
Net Income 2,155,264 2,096,896 263,484 (112,052)
Total Assets 6,543,114 6,245,898 3,546,014 2,896,787
Total Debt 560,381 591,367 606,433 840,761
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Vertex Pharmaceuticals Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Vertex Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Vertex Pharmaceuticals Competitors (29)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Intercept(Biotechnology) Formerly VC-backed New York, NY 000 00000 00000000000 00000
0000000 Formerly VC-backed Boston, MA 0000 000000000
000000 Formerly VC-backed Cambridge, MA 0000 000.00 00000000000 000.00
0000000000 0000000 Formerly VC-backed Novato, CA 000 00000 00000000 00000
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
To view this company’s complete list of competitors, request access »

Vertex Pharmaceuticals Investments & Acquisitions (10)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 0000000000 06-Jun-2019 000000000000000000 00000 Biotechnology
000000 15-May-2019 000000000 Biotechnology 0000000 000000 00.0
00000000 30-Aug-2018 00000 00000 00 000.00 Other Healthcare Technology Systems 00000 000000000 00.0
0000000 0000000000 25-Jul-2017 000000000 00000 00 00000 Other Healthcare Services 0000000 000000 00
Moderna Therapeutics 07-Sep-2016 Later Stage VC 00000 Drug Discovery
To view this company’s complete investment and acquisition history, request access »

Vertex Pharmaceuticals Exits (2)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000 0000000000 07-Sep-2016 00000 00000 00 00000 Completed
  • 2 buyers
Altus Pharmaceuticals 06-Mar-2007 PIPE 0000 Completed
  • 3 buyers
To view this company’s complete exits history, request access »

Vertex Pharmaceuticals Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Vertex Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Vertex Pharmaceuticals Executive Team (23)

Name Title Board
Seat
Contact
Info
Jeffrey Leiden Ph.D Chairman, President and Chief Executive Officer
Paul Silva Senior Vice President, Corporate Controller and Interim Chief Financial Officer
Michael Parini JD Executive Vice President & Chief Legal and Administrative Officer
David Bean Senior Vice President, Finance & CIO
David Altshuler Ph.D Executive Vice President, Global Research, Chief Scientific Officer and Board Member

10 Former Executives

You’re viewing 5 of 23 executives. Get the full list »

Vertex Pharmaceuticals Board Members (9)

Name Representing Role Since Contact
Info
Elaine Ullian Self Board Member 000 0000
Joshua Boger Ph.D Vertex Pharmaceuticals Co-Founder, Board Member & Chairman of Science and Technology Committee 000 0000
Margaret McGlynn Self Board Member 000 0000
Terrence Kearney Self Board Member & Chairman of Audit and Finance Committee 000 0000
Yuchun Lee Self Board Member 000 0000

4 Former Board Members

You’re viewing 5 of 9 board members. Get the full list »